Anti-leukotriene therapy in asthma

Netherlands Journal of Medicine

Volumn 53, Issue 4, 1998, Pages 176-189

  Diamant, Zuzana ^a   Bel, Elisabeth H ^b   Dekhuijzen, P N Richard ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Asthma; Leukotriene biosynthesis inhibitors; Leukotriene receptor antagonists

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; ALLERGEN; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUKOTRIENE SYNTHESIS INHIBITOR; MONTELUKAST; POBILUKAST; PRANLUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CELL COUNT; CHILDHOOD DISEASE; CLINICAL TRIAL; COLD AIR; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EOSINOPHIL; ERRATUM; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG FUNCTION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PROVOCATION TEST; RASH; SYMPTOM;

ASTHMA; FOLLOW-UP STUDIES; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0032190509     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00081-3     Document Type: Erratum

References (103)

1. Djukanovic R, Roche WR, Wilson JWet al. Mucosal inflammation in asthma. Am Rev Respir Dis. 142:1990;434-457.
2. Ebina M, Takahashi T, Chiba T, Motomiya M Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. Am Rev Respir Dis. 148:1993;720-726.
3. Global initiative for asthma. National Institutes of Health, National Heart, Lung, and Blood Institute, January 1995.
4. Barnes PJ, Jonsson B, Klim JB The costs of asthma. Eur Respir J. 9:1996;636-642.
5. Sterk P.J., Fabbri L.M., Quanjer Ph.H.et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J. 6(16):1993;53-83.
6. Cockcroft DW, Murdock KY, Kirby JG, Hargreave FE Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis. 135:1987;264-267.
7. Weersink EJM, Postma DS, Aalbers R, De Monchy JG Early and late asthmatic reaction after allergen challenge. Respir Med. 88:1994;103-114.
8. Diaz P, Gonzalez MC, Galleguillos FRet al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis. 139:1989;1383-1389.
9. Bentley AM, Kay AB, Durham SR Human late asthmatic reactions. Clin Exp Allergy. 27(1):1997;71-86.
10. Holgate ST, Bradding P, Sampson AP Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol. 98:1996;1-13.
11. Lewis RA, Austen KF, Soberman RJ Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 323:1990;6456-6465.
12. Holtzman MJ Arachidonic acid metabolism. Am Rev Respir Dis. 143:1991;188-203.
13. Williams JD, Czop JK, Austen KF Release of leukotrienes by human monocytes on stimulation on their phagocytic receptor for particulate activators. J Immunol. 132:1984;3034-3040.
14. 4. Proc Natl Acad Sci USA. 79:1982;7866-7870.
15. Bochner BS, Undem BJ, Lichtenstein LM Immunological aspects of allergic asthma. Annu Rev Immunol. 12:1994;295-335.
16. Peters SP, MacGlashan DW, Schulman ESet al. Arachidonic acid metabolism in purified human lung mast cells. J Immunol. 132:1984;1972-1979.
17. 4 by human eosinophils. Clin Exp Immunol. 56:1984;716-722.
18. 4 on ionophore A-23187 challenge. J Allergy Clin Immunol. 74:1984;310-315.
19. Sampson AP The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy. 26:1996;995-1004.
20. Drazen JM, Evans JF, Stevens RL, Shipp MA Inflammatory effector mechanisms in asthma. Am J Respir Crit Care Med. 152:1995;403-407.
21. 4 in the human lung. J Clin Invest. 84:1989;1609-1619.
22. 4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol. 55:1994;183-191.
23. Foster A, Chan CC Peptide leukotriene involvement in pulmonary eosinophil migration upon challenge in the actively sensitized guinea pig. Int Arch Allergy Appl Immunol. 96:1991;279-284.
24. 4 and granulocytic infiltration into asthmastic airways. Lancet. 341:1993;989-990.
25. 4 and methacholine on cell differentials in sputum from patients with asthma. Am J Crit Respir Care Med. 155:1997;1247-1253.
26. 4. J Pharmacol Exp Ther. 237:1986;558-562.
27. Gorenne I, Norel X, Brink C Cysteinyl leukotriene receptors in the human lung: what's new? Trends Pharmacol Sci. 17:1996;342-345.
28. 4 in normal and asthmatic subjects in vivo. Eur Respir J. 7:1994;459-466.
29. Turnbull LS, Turnbull LW, Leitch AG, Crofton JW, Kay AB. Mediators of immediate-type hypersensitivity in sputum from patients with chronic bronchitis and asthma. Lancet 1977;i:526-529.
30. Jarjour NN, Calhoun WJ, Schwartz LB, Busse WW Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis. 144:1991;83-87.
31. 2, and other bronchoconstricting prostaglandins in the airway of subjects with mild asthma. Am Rev Respir Dis. 142:1990;126-132.
32. Stenton SC, Court EN, Kingston WPet al. Platelet activating factor in bronchoalveolar lavage fluid from asthmatic subjects. Eur Respir J. 3:1990;408-413.
33. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 81:1988;711-717.
34. Sampson AP, Thomas RU, Costello JF, Piper PJ Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol. 33:1992;423-430.
35. 4 in asthmatic patients. Int J Tissue React. 15:1993;181-184.
36. 4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol. 84:1987;149-155.
37. 4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 84:1989;19-26.
38. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;i:584-588.
39. 4 in the breathing condensate of asthmatics in relation to bronchial challenge test (abstract). Am J Respir Crit Care Med. 151:1995;A679.
40. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 147:1993;215-217.
41. Abraham WM, Burch RM, Farmer SG, Sielczak MW, Ahmed A, Cortes A A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep. Am Rev Respir Dis. 143:1991;787-796.
42. Broide DH, Eisman S, Ramsdell JW, Ferguson P, Schwartz LB, Wasserman SI Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis. 141:1990;563-568.
43. Pliss LB, Ingenito EP, Ingram RH, Pichurko B Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis. 142:1990;73-78.
44. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 89:1992;1111-1119.
45. 4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 144:1991;1411-1413.
46. 4 excretion in exercise-induced asthma. J Appl Physiol. 73:1992;743-748.
47. 4 levels following isocapnic hyperventilation in asthmatics (abstract). Am J Respir Crit Care Med. 151:1995;A678.
48. Diamant Z Experimental interventions in leukotriene- and allergen-induced airway responses in asthma in vivo. PhD thesis 1996, ISBN no 90-9009332 (+ refs. therein).
49. Chafee FH, Settipane GA Aspirin intolerance. 1. Frequency in an allergic population. J Allergy Clin Immunol. 3:1974;193-199.
50. 4 in bronchial asthma. Eur Respir J. 5:1992;693-699.
51. Nasser SMS, Pfister R, Christie PEet al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med. 153:1996;90-96.
52. 4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis. 146:1992;1531-1534.
53. Sladek K, Dworski R, Soja Jet al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med. 149:1994;940-946.
54. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 315:1986;480-484.
55. 4 in humans. Am Rev Respir Dis. 131:1985;368-372.
56. 4 in normal subjects. Am Rev Respir Dis. 133:1986;1127-1132.
57. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis. 144:1991;1053-1057.
58. 4, methacholine, and histamine. Am Rev Respir Dis. 142:1990;1112-1118.
59. 4 in normal subjects: comparison and interaction with methacholine. Am Rev Respir Dis. 136:1987;979-984.
60. 4 does not cause a late asthmatic response in atopic subjects. J Allergy Clin Immunol. 79:1987;141A.
61. 4 in allergen-induced increases in airway smooth muscle in the rat. Am Rev Respir Dis. 148:1993;413-417.
62. 4 in guinea pigs. Clin Exp Allergy. 24:1994;960-968.
63. 4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol. 269:1995;L151-L157.
64. Laitinen LA, Laitinen A Structural and cellular changes in asthma. Eur Respir Rev. 4:1994;348-351.
65. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol. 74:1993;2771-2781.
66. 4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs. Am Rev Respir Dis. 140:1989;1712-1716.
67. 4 antagonist LY293111 on the inflammatory response to allergen challenge in atopic asthmatics (abstract). Am J Respir Crit Care Med. 151:1995;A680.
68. Rossi GA, Crimi E, Lantero Set al. Late-phase asthmatic reaction to inhaled allergen is associated with early recruitment of eosinophils in the airways. Am Rev Respir Dis. 144:1991;379-383.
69. Holroyde MC, Altounyan RE, Cole M, Dixon M, Elliott EV Selective inhibition of bronchoconstriction induced by leukotrienes C and D in man. Adv Prostaglandin Thromboxane Leukot Res. 9:1982;237-242.
70. 4 receptor antagonist. Can J Physiol Pharmacol. 64:1986;1535-1542.
71. 4-induced bronchoconstriction in normal man. J Allergy Clin Immunol. 79:1987;816-821.
72. 4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. J Pharmacol Exp Ther. 246:1988;732-738.
73. 4-induced bronchoconstriction in healthy volunteers. Drug Invest. 3:1991;239-247.
74. 4 in subjects with mild asthma. Br J Clin Pharmacol. 32:1991;512-515.
75. 4 in asthmatics. Pulm Pharmacol. 4:1991;37-42.
76. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 146:1992;358-363.
77. 4 antagonist (verlukast - MK-0679) in asthmatic patients. Pulm Pharmacol. 5:1992;121-125.
78. Calhoun WJ, Williams KL, Simonson SG, Lavins BJ Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am J Respir Crit Care Med. 155:1997;A662.
79. Tamaoki J, Kondo M, Tagaya Eet al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid (abstract). Am J Respir Crit Care Med. 155:1997;A663.
80. Micheletto C, Turco P, Dal Negro R Accolate 20 mg works as steroid sparing in moderate asthma (abstract). Am J Respir Crit Care Med. 155:1997;A664.
81. Leff JA, Israel E, Noonan MJet al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability (abstract). Am J Respir Crit Care Med. 155:1997;A976.
82. Fujimura M, Sakamoto S, Kamio Y, Matsuda T Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 87:1993;133-138.
83. 4 receptor antagonist, in patients with chronic asthma (abstract). J Allergy Clin Immunol. 87:1991;309.
84. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 150:1994;618-623.
85. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 98:1996;528-534.
86. Barnes NC, Pujet J-Cet al. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo-controlled, multicentre clinical study in asthma. Thorax. 52:1997;523-527.
87. 1-receptor antagonist, on eosinophil counts and ECP in induced sputum before and after allergen challenge in asthmatics (abstract). Am J Respir Crit Care Med. 155:1997;A976.
88. Leff JA, Pizzichini E, Efthimiadis Aet al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial (abstract). Am J Respir Crit Care Med. 155:1997;A977.
89. McGill KA, Busse WW Zileuton. Lancet. 348:1996;519-524.
90. Storms W, Friedman BS, Zhang Jet al. Treating asthma by blocking the lipoxygenase pathway (abstract). Am J Respir Crit Care Med. 151:1995;A377.
91. Virchow JC, Noller PS, Wiessmann KJet al. Multicenter trial of BAY-x1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma (abstract). Am J Respir Crit Care Med. 151:1995;A377.
92. Liu MC, Dubé LM, Lancaster J Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol. 98:1996;859-871.
93. Israel E, Cohn J, Dube L, Drazen Jet al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with athma. A randomized controlled trial. JAMA. 275:1996;931-936.
94. Fischer AR, McFadden CA, Frantz Ret al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 152:1995;1203-1207.
95. Kane GC, Pollice M, Kim C-Jet al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 97:1996;646-654.
96. Dahlén S-E, Nizankowska E, Dahlén Bet al. The swedish-polish treatment study with the 5-lipoxygenase inhibitor zileuton in aspirin-intolerant asthmatics (abstract). Am J Respir Crit Care Med. 151:1995;A376.
97. Dekhuijzen PNR, Bootsma GP, Wielders PLML, Van den Berg LRM, Festen J, Van Herwaarden CLA Effects of single-dose Zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. Eur Respir J. 10:1997;2749-2753.
98. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 152:1995;897-905.
99. Drazen JM, Israel E Asthma: a solution of half the puzzle? Am Rev Respir Dis. 144:1991;743-744.
100. Ikeda K, Hyashi M, Obata H, Fujita H, Nakanishi T, Izumi T Two weeks observation of pranlukast (ONO-1078, leukotriene receptor antagonist) by peak expiratory flow rate (PEFR) was enough to evaluate clinical efficacies in severe chronic adult asthmatics (abstract). Am J Respir Crit Care Med. 155:1997;A664.
101. Robuschi M, Riva E, Fuccella LMet al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK and F 104353). Am Rev Respir Dis. 145:1992;1285-1288.
102. TM), sodium cromoglycate or placebo on exercise-induced bronchoconstriction in asthmatic adolescents. Am J Respir Crit Care Med. 155:1997;A665.
103. Knorr BA, Matz J, Bernstein JAet al. Montelukast (MK-0476) improves asthma over a 2 month treatment period in 6- to 14-year olds. Am J Respir Crit Care Med. 155:1997;A664.